The necessity of routine screening for deep vein thrombosis before surgery

Hideki Endoh a,⁎, Kazuaki Shiratori b,⁎, Miki Horigome c,⁎, Dai Uematsu d, Takuo Takehana d, Taro Sakamoto d, Kazuyuki Fukushima e, Hiroyuki Ishige f,⁎, Hitoshi Watanabe h,⁎, Yoshikazu Yazaki c,⁎

a Department of Thoracic Surgery, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan
b Department of Cardiovascular Surgery, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan
c Department of Cardiology, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan
d Department of Orthopedic Surgery, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan
e Department of Digestive Surgery, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan
f Department of Breast Surgery, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan
g Working Group of Venous Thrombosis Prevention, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan
h General Manager, Saku Central Hospital Advanced Care Center, Saku, Nagano, Japan

⁎ Corresponding author. 3400-28, Nakagomi, Saku, Nagano, 385-0051, Japan.
E-mail address: hidendo509@yahoo.co.jp (H. Endoh).

https://doi.org/10.1016/j.amsu.2022.103627

Received 29 January 2022; Received in revised form 11 April 2022; Accepted 11 April 2022

1. Introduction

The incidence of perioperative symptomatic pulmonary thromboembolism (PSPTE) is 2.2–4.4 per 10,000 cases, with the number of PSPTE cases and the fatality rate reported to have decreased in the past 10 years in Japan [1]. Guidelines of the National Institute for Health and Care Excellence recommend mechanical prophylaxis of venous thromboembolism (VTE), such as anti-embolism elastic stockings (ES), foot impulse devices, and intermittent pneumatic compression (IPC) devices, for patients who undergo gastrointestinal, gynecological, thoracic, urological, and neurological (cranial or spinal) surgery [2–4]. Although adding pharmacological VTE prophylaxis for patients who have a low risk of major bleeding has been recommended, it is difficult to judge whether the risk of major bleeding is low. For orthopedic surgery (elective hip or knee replacement and hip fracture), VTE prophylaxis could be performed using edoxaban, fondaparinux, or low-molecular-weight heparins (LMWHs, enoxaparin) in Japan. However, there is no contraindication to initiating pharmacological VTE prophylaxis several hours before and after surgery.

We organized a working group for the prevention of death from acute
pulmonary thromboembolism in 2008 and analyzed the data for 8 years. This study primarily aimed to evaluate the results of screening for preoperative deep vein thrombosis (DVT). The secondary aim was to assess the development of postoperative VTE with or without subsequent additional pharmacological prophylaxis in addition to routine mechanical prophylaxis.

2. Materials and Methods

2.1. Study design and data collection

This was a single-institution, case-control study approved by the Institutional Review Board (R201604-02). This study has also been registered in the Research Registry with the number ‘UMIN000046740’ ([https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recepti on=R000053271](https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?reception=R000053271)). The study was performed in accordance with the ethical standards laid down in the most recent version of the Declaration of Helsinki. The need for written informed consent was waived, and brief information on this study was disclosed on the hospital website to guarantee a patients’ opportunity to refuse their participation in the study (opt-out method). The work has been reported in the line with the STROCSS criteria [5].

The patient records/information was anonymized and de-identified before analysis. The total number of patients who underwent surgery under general anesthesia between 2009 and 2013 in Saku Central Hospital and between 2014 and 2016 in Saku Central Hospital Advanced Care Center, Japan, was 24,826. Of the patients who planned to have surgery under general anesthesia, 5345 underwent an ultrasound of the leg (leg-US) to examine for DVT after D-dimer screening.

In 2008, we participated in the Japanese collaborative action for safe medical treatment, in which we aimed at the reduction of mortality from VTE. One of the main endeavors was the prevention of VTE after surgical treatment, and another challenge was the early detection and screening tests before surgery. We then began D-dimer screening for perioperative patients.

All patients who planned to undergo surgery under general anesthesia were referred to the perioperative examination and care center in the hospital, and the VTE risk score was evaluated according to the Japanese Thrombosis Association guidelines for diagnosis, treatment, and prevention of pulmonary thromboembolism and deep vein thrombosis (Japanese Circulation Society 2017) [2]. Patients at intermediate to higher risk for VTE were managed using ES or IPC devices in the postoperative period, and additional anticoagulant medications (heparin calcium) were recommended for high-risk patients. As there was concern that thrombus might float up into the pulmonary artery by IPC during the perioperative period if DVT was found before the operation, DVT screening was performed preoperatively and ES, not IPC, was used more commonly for PE prophylaxis.

First, the measurement of D-dimer was initiated, a cut-off value was not clearly defined, and the number of patients with values more than 3.0 µg/mL was selected. For approximately 10% of all test samples, whole leg-ultrasound (US) could be performed in our examination room. Patients whose D-dimer was greater than 3.0 µg/mL underwent leg-US to check for thrombus in the femoral, popliteal, saphenous, or soleus muscle (soleal) vein. However, the D-dimer test was discontinued due to an inspection by the medical insurance regime in 2011, and since then, only leg-US without d-dimer screening has been performed for almost all patients indicated as preoperative screening according to risk evaluation. If DVT into the femoral vein was found, enhanced computed tomography was ordered, and a cardiologist was consulted. If DVT was found in the distal popliteal vein, an IPC device was prohibited.

2.2. Analysis of the outcomes of DVT cases

The medical records of the 217 patients who were diagnosed with DVT using leg-US between 2014 and 2016 were analyzed retrospectively. In all general anesthesia surgery cases, DVT echo selection criteria were set by the evaluation score of each department of surgery and risk score as follows: predicted operation time, age over 60 years, operation for patients with cancer, prior VTE, preoperative bed rest over 48 h (recumbency), and edema of lower limbs or swollen legs. Leg-US was performed by a laboratory technician and the result with detailed findings including organized thrombus when it appeared hyperechoic and stuck, and pictorial images were reported to surgeons. The prevention method was selected by each surgeon and the mechanical method (ES or IPC) was performed with/without a therapeutic dose of anticoagulants if DVT was found. The location of the thrombus was assigned to the most proximal vein if multiple thrombi were detected. The use of anticoagulant agents (yes/no), the frequency if used, and the performance if a follow-up examination within 3 months after the operation were examined. In Japan, although only edoxaban is approved DOAC for prophylaxis for DVT in orthopedic surgery, 217 cases were diagnosed with DVT and another DOAC (rivaroxaban, apixaban) also could be used. The mortality rate and the need for intensive care due to PE before discharge from the hospital were also investigated.

2.3. Statistical analysis

The Mann-Whitney U test was used to examine differences in continuous variables, and the chi-square test was used for categorical variables. Multivariate logistic regression analysis was performed to identify significant clinicopathological variables to differentiate improvement of thrombi using leg-US, in which each variable had a p-value < 0.1. For analyses, p < 0.05 was considered significant. JMP software (13.1.0, SAS Institute, Cary, NC, USA) was used for all analyses.

3. Results

3.1. Screening for DVT before surgery

In 2009, the first year of DVT screening, D-dimer screening with a cut-off value of 3.0 µg/mL was initiated, and 341 patients (11.5% of cases planned for surgery under general anesthesia) were screened as leg-US candidates. Shortly after, more than 30% of all surgical cases were screened using leg-US independently of the D-dimer values according to their risk evaluation. Moreover, D-dimer screening was discontinued in the latter 4 of the 8 years due to an inspection by the medical insurance regime. Approximately 9.5%–18.4% of tested cases (1.4–4.0% of all surgical cases underwent general anesthesia) were diagnosed with DVT, and the results were independent of D-dimer screening (Suppl. Fig. 1). Over the 8 years, a total of 5345 patients underwent leg-US, and DVT was found in 648 patients (12.1%). In this period, no deaths due to postoperative PE were reported.

3.2. Prognosis of patients who underwent surgery with DVT

Next, the prognosis of patients with DVT diagnosed preoperatively by leg-US between 2014 and 2016 was examined. In this period, 1849 of the total 10,346 patients who underwent surgery under general anesthesia were examined using leg-US, and 217 patients (11.7%) were diagnosed with DVT.

The demographic characteristics of the patients analyzed in this study are shown in Table 1. When DVT location was divided into two groups (proximal type for the external iliac, femoral, or superficial femoral veins; or distal type for popliteal, gastrocnemius, or soleal veins) with 74 being of the proximal type and 154 of the distal type. The most common location of DVT was the soleal vein (53.7%), followed by the femoral vein (22.1%). Overall, 70% of patients were operated on at the department of digestive or general surgery and department of orthopedic surgery. Laboratory technicians recorded the thrombus as organized thrombus when it seemed hyperechoic and stuck; 136 cases (62.7%) were determined to be organized thrombi. D-dimer was measured in 171...
patients; the mean value was 12.7 μg/mL, and the median was 5.9 μg/mL. It was found that 28.7% of patients with DVT had a low D-dimer level (<3 μg/mL), and the same number of patients had a high D-dimer level (>10 μg/mL). The D-dimer level of all patients with DVT varied; thus, DVT was not necessarily associated with D-dimer elevation (Fig. 1).

Of the total 217 patients, all were managed using anti-embolism ES; and 111 patients took anticoagulants: 44 heparin with/without warfarin, 21 fondaparinux, 18 enoxaparin, 12 therapeutic doses of direct oral anticoagulants (DOACs; edoxaban, rivaroxaban, apixaban), eight warfarin only, and eight other consumed oral antiplatelet medications (aspirin, clopidogrel). The treatment period for heparin, fondaparinux, or enoxaparin in 83 patients was 1–60 days (median 6 days), and 52% of the patients subsequently received warfarin or DOACs in therapeutic doses. Fig. 1 and Table 2 show that there was no selection bias in anticoagulant agent use, such as the D-dimer level and organized thrombus, except for proximal thrombus and no malignant disease.

Follow-up leg-US was performed in 88 patients to determine whether there was an improvement or no change after several days or months. Although 129 patients did not undergo follow-up examination, no patient developed PE or died. Of the follow-up patients, 40 patients were considered improved, whereas 48 showed no change. Moreover, the numbers with improvement and without change were not very different in all categories, including with or without medications, and any kinds of medications except fondaparinux (Table 3). The chi-square test examining the category related to improvement on the follow-up leg-US also showed that anticoagulant use for DVT discovered before surgery was not related to shrinkage of thrombi. In this analysis, significant differences in thrombus improvement were found for DVT with non-organized thrombus, orthopedic surgery, cases with D-dimer elevation, and fondaparinux use (Table 4). Multiple logistic regression

Table 1
Demographic characteristics of 217 patients with positive US screening for DVT.

| Variable                  | No. Of patients |
|---------------------------|-----------------|
| Age (y)                   | 29-95 (median 78) |
| Sex                       |                 |
| Female                    | 123             |
| Male                      | 94              |
| Leg Side                  |                 |
| Bilateral                 | 53              |
| Right                     | 84              |
| Left                      | 80              |
| DVT position              |                 |
| Central (above popliteal vein) | 86         |
| External iliac vein       | 2               |
| Femoral vein              | 48              |
| Superficial femoral vein  | 18              |
| Popliteal vein            | 18              |
| Peripheral                | 131             |
| Gastrocnemius vein        | 8               |
| Soleal vein               | 123             |
| Surgical categories       |                 |
| Digestive and general surgery | 78 (2.5%)    |
| Orthopedic surgery        | 73 (4.2%)       |
| Cardiovascular surgery    | 16 (1.7%)       |
| Plastic surgery           | 11 (2.2%)       |
| Urology                   | 8 (2.9%)        |
| Neurosurgery              | 7 (2.9%)        |
| Obstetrics and gynecology | 7 (1.4%)        |
| Breast/Respiratory        | 5/2 (1.1/0.4%)  |
| Thyroid/Otolaryngology    | 1/1 (0.6/0.1%)  |
| ESD/Nephrology/others    | 1/4/3 (0.6/12.5/25%) |

US: ultrasound, DVT: deep venous thrombosis, ESD: endoscopic submucosal dissection. * (frequency (% of occurrence in each surgery).

Fig. 1. D-dimer levels before operation of 217 deep vein thrombosis (DVT) cases between 2014 and 2016. Blue column: number of DVT diagnoses Orange column: cases of pharmacological prophylaxis for DVT. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
Table 3
Outcomes after medical intervention for patients with VTE risk.

| Prognosis         | Improved | No change | No follow-up | Total |
|-------------------|----------|-----------|--------------|-------|
| No medication     | 40       | 48        | 129          | 217   |
| Antithrombotic    | 13       | 15        | 78           | 106   |
| Anticoagulant      | 26       | 32        | 45           | 103   |
| Fondaparinux      | 13       | 5         | 3            | 21    |
| Enoxaparin        | 2        | 6         | 10           | 18    |
| Heparin           | 7        | 14        | 23           | 44    |
| DOAC              | 3        | 6         | 3            | 12    |
| Warfarin          | 1        | 1         | 6            | 8     |

Table 4
Chi-squared test for improvement of DVT on follow-up (total 88 cases).

| Prognosis         | Improved | No change | \( P \)  |
|-------------------|----------|-----------|----------|
| Sex               |          |           | 0.9371   |
| Male              | 17       | 20        |          |
| Female            | 23       | 28        |          |
| Age (y)           |          |           |          |
| \( \leq 78 \)     | 19       | 25        | 0.6685   |
| \( > 78 \)        | 21       | 23        |          |
| Site              |          |           | 0.7533   |
| Proximal          | 18       | 20        |          |
| Distal            | 22       | 28        |          |
| Bilateral         |          |           | 0.1287   |
| Bilateral         | 9        | 18        |          |
| Unilateral        | 31       | 30        |          |
| Organizing        |          |           | 0.0040   |
| –                 | 22       | 12        |          |
| +                 | 18       | 16        |          |
| Surgery           |          |           | \(< 0.0001 \) |
| Orthopedic        | 29       | 13        |          |
| Others            | 11       | 35        |          |
| Malignancy        |          |           | 0.0238   |
| Cancer            | 7        | 19        |          |
| Benign            | 33       | 29        |          |
| D-dimer (μg/mL)   |          |           | 0.0018   |
| \( < 10 \)        | 14       | 30        |          |
| \( \geq 10 \)     | 20       | 9         |          |
| Anticoagulant use |          |           | 0.8695   |
| –                 | 14       | 16        |          |
| +                 | 26       | 32        |          |
| Injection duration (days) |        |           | 0.3765   |
| \( < 4 \)        | 23       | 32        |          |
| \( \geq 4 \)     | 17       | 16        |          |
| Fondaparinux      |          |           | 0.0106   |
| Yes               | 13       | 5         |          |
| No                | 27       | 43        |          |

Table 5
Multivariate logistic regression analysis to identify clinicopathological variables related to DVT shrinkage.

| Variable                        | Odds ratio | 95%CI       | p-value |
|---------------------------------|------------|-------------|---------|
| Organized, No/Yes               | 4.614      | 1.469–16.13 | 0.0084  |
| D-dimer, >10/≤10 μg/mL          | 3.595      | 1.998–12.61 | 0.0343  |
| Orthopedic surgery/others       | 6.528      | 1.466–38.80 | 0.0127  |
| Malignancy, Yes/No              | 2.025      | 0.378–13.45 | 0.4174  |
| Fondaparinux, Yes/No            | 1.969      | 0.457–8.957 | 0.3622  |

VTE: venous thromboembolism, DOAC: direct oral anticoagulant (edoxaban, rivaroxaban, apixaban).

* Antithrombotic: aspirin, clopidogrel, cilostazol.

DVT: deep venous thrombosis

4. Discussion

In this study, the avoidance deaths caused by acute PE (thrombosis) in our hospital for 8 years was reviewed, and no death was reported. This study aimed to analyze whether screening for DVT was meaningful; and whether asymptomatic DVT found by preoperative testing should be treated. DVT screening is important for VTE prevention; however, recently, screening was not evaluated positively as asymptomatic cases were observed with unexpected frequency.

In these cases, the D-dimer levels varied widely, and they were often high, particularly in cardiovascular and orthopedic surgery cases. Sun reported that 86.4% of patients with stroke had a D-dimer level of 500 ng/mL, and 9.5% were diagnosed with DVT using US [6]. Osaki reported that the incidence of DVT was 4.4% (7/160) and 7.2% (11/153) before and after gastric cancer surgery, respectively [7]. A multinational Asian study based on postoperative screening reported a VTE incidence comparable to that reported in Western patients [8].

The second concern was whether anticoagulants should be used after surgery, and the answer might be “no.” Heparin was used safely based on the surgeon’s decision in some cases, and no use of medication might be selected with a report of organized thrombus. Some patients might be rescued from PE by injection of anticoagulant agents; however, no patient was reported to be admitted to an intensive care unit even if no medication was given for preoperatively identified DVT or no follow-up examination was performed. Nakagawa et al. reported a randomized, controlled study for preventing VTE after laparoscopic colorectal cancer surgery with or without enoxaparin [9]. There was no difference in the incidence of VTE between the enoxaparin group (12.3%) and the IPC group (11.9%). Enoxaparin was initiated 24–36 h after surgery and skipped on the morning of removal of the epidural catheter 2 or 3 days after surgery. Epidural anesthesia after surgery is generally performed and concomitant use with anticoagulants is debatable. Another Japanese randomized, controlled study reported that the incidence of VTE in the enoxaparin group was 1.2% [10]. Whether there is a difference in asymptomatic VTE between Japanese and Western populations is controversial [11]. Loh et al. reported that pharmacological prophylaxis in addition to mechanical prophylaxis (IPC pumps) after total knee arthroplasty surgery does not reduce the incidence of VTE [12]. The use of mechanical and pharmacological prophylaxis did not lower the risk of developing DVT (incidence of 5.9% compared with mechanical prophylaxis incidence of 4.6%).

Patients who undergo total knee arthroplasty have been shown to have a high risk for VTE, leading to recommendations in international guidelines to use a combination of mechanical and pharmacological thromboprophylaxis before and after the procedure [13]. Pharmacological thromboprophylaxis of VTE has been recommended to reduce the prevalence of postoperative DVT on that assumption. The practice of routine postoperative pharmacological thromboprophylaxis has primarily been based on Western literature to date, and the recent acknowledgment of studies showing a lower incidence of thromboembolism in Asia has led to questions regarding the need for routine pharmacological thromboprophylaxis for patients undergoing surgery [14]. In contrast, Colwell et al. showed that intermittent pneumatic compressive IPC devices (ICPDs) were just as effective as enoxaparin in preventing proximal and distal DVT and PE events in hip arthroplasty patients; however, resulted in a much lower bleeding risk (1.3% ICPD and 4.3% LMWH) in a multicenter, randomized, controlled trial comparing ICPD to enoxaparin [15]. In this study, postoperative thrombus shrinkage was more common in orthopedic cases. This might be owing to the use of fondaparinux in such cases with adequate treatment duration, without the use of epidural anesthesia with fresh thrombus formation possibly common.

Singh et al. recommended full anticoagulation until the patient is ambulatory or the follow-up duplex scan is negative [16]. In their study, the incidence of clot propagation into proximal veins was approximately 7%. Of the present cases, postoperative PE occurred in cases that did not show preoperative DVT (data not shown), and none of the known DVT cases developed PE.

There are some limitations to the present study. It had a retrospective design, and the study was based on a small sample size with limited medical records. As leg-US was performed to diagnose DVT, the measurement of thrombus size was challenging, and evaluation of remission, whether thrombus was decreased on the follow-up test, was subjective.
5. Conclusion

In conclusion, this analysis showed that routine DVT screening for all surgical patients might not be necessary, and asymptomatic DVT might not always require medical treatment such as anticoagulant agents, although careful management including anticoagulant use is needed for patients following orthopedic surgery, those with a high D-dimer level, and those who occasionally show non-organized thrombus.

Ethical approval

This retrospective study was approved by the Institutional Review Board (R201604-02) and conducted in accordance with the Declaration of Helsinki.

Source of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Authors’ contributions

HE, KS, MH, HW, YY: study conception, design, data analysis, and drafting of the manuscript. DU, TT, TS, KF, HI: data collection. HE, KS, MH, YY: interpretation, critical revision of the manuscript. All authors contributed to the article and approved the submitted version.

Trail registry number

Name of the registry: A study to evaluate routine screening for deep vein thrombosis before surgery.

Unique Identifying number or registration ID: UMIN000046740.

Hyperlink to your specific registration (must be publicly accessible and will be checked): https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000053271.

Guarantor

Hideki Endoh, M.D.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Consent

Not applicable.

Declaration of competing interest

The authors declare that they have no conflict of interest.

Acknowledgments

The authors are grateful for organizer and manager of Satoshi Izawa, M.D., and also for the support and efforts of the prevention of VTE working group: Yuka Ogiso (RN), Tomoko Li (RN), Yukie Mitsubishi (RN), Aiko Mizuma (RN), Ritsuko Yui (RN), Hiromi Nakajima (RN), Kazue Okiura (RN), Mieko Kurumizawa (RN), Mami Hinata (RN), Satoshi Komiyama (ME), Megumi Hakoyama (Staff), Satomi Takahashi (Staff), Tomo Kawabata (Staff), Katsumi Takeshige (Staff), and other medical office staff.

We would like to thank Editage (www.editage.com) for English language editing.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jamsu.2022.103627.

References

[1] M. Kuriwia, H. Morimatsu, K. Tsuzuki, K. Irita, M. Samuki, H. Nakatuka, et al., Changes in the incidence, case fatality rate, and characteristics of symptomatic perioperative pulmonary thromboembolism in Japan: results of the 2002-2011 Japanese society of anesthesiologists perioperative pulmonary thromboembolism (JSA-PTE) study, J. Anesth. 29 (2015) 433–441.

[2] JCS Joint Working Group. Guidelines for the diagnosis, treatment and prevention of pulmonary thromboembolism and deep vein thrombosis (JCS 2017). (Japanese). j-crr.or.jp/old/guideline/pdf/jcsc2017_t.pdf.

[3] National Clinical Guideline Centre, Venous Thromboembolism in over 16: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis or Pulmonary Embolism, 2018. www.nice.org.uk/guideline/rg89 Date. (Accessed 15 August 2021).

[4] M.K. Gould, D.A. Garcia, S.M. Wren, P.J. Karanicolas, J.I. Arcelus, J.A. Heit, et al., Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines, Chest 141 (Supplement) (2012) e227–277S.

[5] G. Mathew, A. Agba, S. Group, Stross, Strengthening the reporting of cohort, cross-sectional and case-control studies in surgery, Int. J. Surg. 96 (2021) (2021), 106155.

[6] M.C. Sun, M.S. Li, Intervention for diagnosis of deep vein thrombosis in acute stroke patients: a hospital-based study, PLoS One 9 (2014), e14094.

[7] T. Osaki, H. Saito, Y. Fukumoto, Y. Kono, Y. Murakami, Y. Shishido, et al., Risk and incidence of perioperative deep vein thrombosis in patients undergoing gastric cancer surgery, Surg. Today 48 (2018) 525–533.

[8] F. Pioveola, C.J. Wang, H. Lu, K. Lee, L.H. Lee, W.C. Lee, A.G.G. Turpie, A.S. Gullus, A. Planes, R. Passera, A. Rouillon, A.I.D.A. investigators, Deep-vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography, J. Thromb. Haemostasis 3 (2015) 2664–2670.

[9] K. Nakagawa, J. Watanabe, M. Ota, Y. Suwa, S. Suzuki, M. Momiyama, A. Iishi, Y. Saigusa, T. Yamakawa, C. Kunitake, I. Endo, Efficacy and safety of enoxaparin for preventing venous thromboembolic events after laparoscopic colorectal cancer surgery: a randomized-controlled trial (YOCOG 1404), Surg. Today 50 (2020) 68–75.

[10] M. Sakon, T. Kobayashi, T. Shimizu, Efficacy and safety of enoxaparin in Japanese patients undergoing curative abdominal or pelvic cancer surgery: results from a multicenter, randomized, open-label study, Thromb. Res. 125 (2010) e65–70.

[11] N.A. Zakai, L.A. McClure, Racial differences in venous thromboembolism, J. Thromb. Haemostasis 9 (2011) 1877–1882.

[12] J.J.M. Loh, S. Chan, K.L. Wong, S. de Mel, E.S. Yap, Chemoprophylaxis in addition to mechanical prophylaxis after total knee arthroplasty does not reduce the incidence of venous thromboembolism, Thromb. J. 17 (2019) 9.

[13] J.W. Eikelboom, G. Kallikayen, N. Fagel, J. Hirsh, American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: what are the implications for clinicians and patients? Chest 13 (2009) 513–520.

[14] K.L. Wong, R. Daguman, K.H. Lim, L. Shen, K. Lingaraj, Incidence of deep vein thrombosis following total hip arthroplasty: a Doppler ultrasonographic study, J. Orthop. Surg. 19 (2011) 50–53.

[15] C.W. Colwell Jr., M.A. Mont, M.A. Ritter, R.T. Trousdale, K. Loeser, A. Spitzer, T.K. Donaldson, D.E. Padgett, Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin, J Bone Joint Surg Am 92 (2010) 527–535.

[16] K. Singh, D. Yakoub, F. Giangola, M. DeCicca, C.A. Putel, F. Marrzouk, G. Giangola, Early follow-up and treatment recommendations for isolated calf deep venous thrombosis, J. Vasc. Surg. 55 (2012) 136–140.